


# Patent Claims

## 1. Compounds of the formula I

5

10



I

15

in which

$R^1$ ,  $R^5$  each, independently of one another, denote H, OH, OA, OAc or methyl,

20

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  each, independently of one another, denote H, OH, OA, OAc,  $OCF_3$ , Hal,  $NO_2$ ,  $CF_3$ , A, CN,  $OSO_2CH_3$ ,  $SO_2CH_3$ ,  $NH_2$  or  $COOH$ ,

$R^{11}$  denotes H or  $CH_3$ ,

A denotes alkyl having 1, 2, 3 or 4 C atoms,

25

X denotes  $CH_2$ ,  $CH_2CH_2$ ,  $OCH_2$  or  $-CH(OH)-$ ,

Hal denotes F, Cl, Br or I,

and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

30

## 2. Compounds according to Claim 1 in which

$R^1$  denotes H, methyl, OA, OAc or OH,

$R^5$  denotes H, methyl or OA,

35

$R^2$  denotes H,  $NO_2$ , Hal, OA, A or  $COOH$ ,

$R^4$  denotes H, Hal, A,  $CF_3$ ,  $NO_2$  or OA

- 5  
10  
15
- $R^3$  denotes OH, OAc,  $SO_2CH_3$ , Hal,  $CF_3$ ,  $OCF_3$ , COOH, OA, H, A or  $NO_2$ ,  
 $R^6$  denotes H, A or OA,  
 $R^7$  denotes OA, H, Hal, OH,  $CF_3$ ,  $NO_2$  or  $NH_2$ ,  
 $R^8$  denotes H, OH, OA or Hal,  
 $R^9$  denotes H, A, Hal,  $OSO_2CH_3$  or OH,  
 $R^{10}$  denotes H, A, OA or Hal,  
 $R^{11}$  denotes H or  $CH_3$ ,  
A denotes alkyl having 1, 2, 3 or 4 C atoms,  
X denotes  $CH_2$ ,  $CH_2CH_2$ ,  $OCH_2$  or  $-CH(OH)-$ ,  
Hal denotes F, Cl, Br or I,  
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

- 20  
25  
30  
35
3. Compounds according to Claim 1 or 2 in which  
 $R^1$  denotes methyl, OA or OH,  
 $R^5$  denotes H or methyl,  
 $R^2$  denotes H,  $NO_2$  or Hal,  
 $R^4$  denotes H or Hal,  
 $R^3$  denotes OH or OAc,  
 $R^6$  denotes H,  
 $R^7$  denotes OA, H, Hal, OH,  $CF_3$  or  $NO_2$ ,  
 $R^8$  denotes H, OH or Hal,  
 $R^9$  denotes H, A, Hal,  $OSO_2CH_3$  or OH,  
 $R^{10}$  denotes H, A or Hal,  
 $R^{11}$  denotes H or  $CH_3$ ,  
A denotes alkyl having 1, 2, 3 or 4 C atoms,  
X denotes  $CH_2$ ,  $CH_2CH_2$ ,  $OCH_2$  or  $-CH(OH)-$ ,  
Hal denotes F, Cl, Br or I,  
and the pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to Claim 1, 2 or 3 in which
- 5       $R^1$       denotes OH,  $OCH_3$  or methyl,  
          $R^5$       denotes H,  
          $R^2$       denotes H,  
          $R^4$       denotes H,  
          $R^3$       denotes OH,  
          $R^6$       denotes H,  
          $R^7$       denotes OH,  
10       $R^8$       denotes H, OH or Hal,  
          $R^9$       denotes H, A, Hal,  $OSO_2CH_3$  or OH,  
          $R^{10}$      denotes H, A or Hal,  
          $R^{11}$      denotes H or  $CH_3$ ,  
15      A        denotes alkyl having 1, 2, 3 or 4 C atoms,  
         X        denotes  $CH_2$ ,  $CH_2CH_2$ ,  $OCH_2$  or  $-CH(OH)-$ ,  
         Hal     denotes F, Cl, Br or I,  
         and the pharmaceutically usable derivatives, salts, solvates and  
         stereoisomers thereof, including mixtures thereof in all ratios.  
20
5. Compounds according to Claim 1 selected from the group
- N-(4-hydroxy-2-methoxybenzylidene)-(3-hydroxyphenyl)aceto-  
         hydrazide,  
25      N-[1-(4-hydroxy-2-methoxyphenyl)ethylidene]-(3-hydroxy-  
         phenyl)acetohydrazide,  
         N-(4-hydroxy-2-methoxybenzylidene)-(3-methoxyphenyl)aceto-  
         hydrazide,  
30      N-(3-fluoro-4-hydroxybenzylidene)phenylacetohydrazide,  
         N-(4-hydroxy-2-methoxybenzylidene)-(4-hydroxyphenyl)aceto-  
         hydrazide,  
         N-(4-hydroxy-2-methoxybenzylidene)-(3,4-dichlorophenyl)aceto-  
         hydrazide,  
35      N-(4-hydroxy-2-methoxybenzylidene)-m-tolylacetohydrazide,  
         N-(4-hydroxy-2-methoxybenzylidene)-o-tolylacetohydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(2-chlorophenyl)aceto-  
hydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(3-chlorophenyl)aceto-  
hydrazide,

5

N-(4-hydroxy-2-methoxybenzylidene)-(4-fluorophenyl)aceto-  
hydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(2-chloro-4-fluorophenyl)-  
acetohydrazide,

10

N-(4-hydroxy-2-methoxybenzylidene)-(3-fluorophenyl)aceto-  
hydrazide,

N-(4-hydroxybenzylidene)-(3-methoxyphenyl)acetohydrazide,

N-(4-hydroxy-2,6-dimethylbenzylidene)-(3-methoxyphenyl)-  
acetohydrazide,

15

N-(3-fluoro-4-hydroxybenzylidene)-(3-methoxyphenyl)aceto-  
hydrazide,

N-[1-(4-hydroxy-2-methoxyphenyl)ethylidene]-(3-methoxy-  
phenyl)acetohydrazide,

20

N-(4-hydroxy-2-methoxybenzylidene)-(3-methylsulfonyloxy-  
phenyl)acetohydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(3,5-dihydroxyphenyl)-  
acetohydrazide,

25

N-(3-fluoro-4-hydroxybenzylidene)-(3-fluorophenyl)acetohydra-  
zide,

N-(4-acetoxy-2-methoxybenzylidene)-(3-methoxyphenyl)aceto-  
hydrazide,

30

N-(4-hydroxy-2-methoxybenzylidene)-(3-trifluoromethylphenyl)-  
acetohydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-3-(3-methoxyphenyl)-  
propiohydrazide,

35

N-(2,4-dihydroxybenzylidene)-(3-methoxyphenyl)acetohydra-  
zide,

N-(4-hydroxy-2-methoxybenzylidene)-(3-methoxyphenoxy)-  
acetohydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(3-nitrophenyl)aceto-  
hydrazide,

N-(5-chloro-2-hydroxybenzylidene)-(3-methoxyphenyl)aceto-  
hydrazide,

N-(2-hydroxy-5-nitrobenzylidene)-(3-methoxyphenyl)aceto-  
hydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-2-hydroxy-2-phenylaceto-  
hydrazide,

N-(2-ethoxy-4-hydroxybenzylidene)-(3-methoxyphenyl)aceto-  
hydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(3-bromophenyl)aceto-  
hydrazide,

N-[1-(4-hydroxyphenyl)ethylidene]-(3-methoxyphenyl)aceto-  
hydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(3,5-difluorophenyl)aceto-  
hydrazide,

N-(4-hydroxy-2-methylbenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2-ethoxy-4-hydroxybenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2-methoxy-4-hydroxy-6-methylbenzylidene)-(3-hydroxy-  
phenyl)acetohydrazide,

N-(2-methoxy-4-hydroxybenzylidene)-(2-fluorophenyl)aceto-  
hydrazide,

N-(2,4-dihydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-5-chlorobenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(4-methylsulfonylbenzylidene)-(3-hydroxyphenyl)acetohydra-  
zide,

N-(2,6-dimethyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2-methoxy-4-hydroxybenzylidene)-(3-hydroxy-4-methoxy-  
phenyl)acetohydrazide,

5

N-(2-methoxy-4-hydroxybenzylidene)-(2,3-dimethoxy-  
phenyl)acetohydrazide,

N-(2-methoxy-4-hydroxybenzylidene)-(3-aminophenyl)aceto-  
hydrazide,

10

N-(2,4-dihydroxy-6-methylbenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2-methoxy-4-hydroxybenzylidene)-(2-methyl-3-methoxy-  
phenyl)acetohydrazide,

15

N-(4-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(4-iodobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-3-bromo-5-chlorobenzylidene)-(3-hydroxyphenyl)-  
acetohydrazide,

20

N-(2-hydroxy-5-tert-butylbenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2-hydroxy-5-bromobenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

25

N-(2-hydroxy-5-trifluoromethoxybenzylidene)-(3-hydroxyphenyl)-  
acetohydrazide,

N-(2-hydroxy-3-methoxy-5-nitrobenzylidene)-(3-hydroxyphenyl)-  
acetohydrazide,

30

N-(4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(4-hydroxy-2-methoxybenzylidene)-(3-ethoxyphenyl)aceto-  
hydrazide,

N-(2-hydroxy-3,5-dichlorobenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

35

N-(2-hydroxy-5-iodobenzylidene)-(3-hydroxyphenyl)acetohydra-  
zide,

N-(2-hydroxy-3-methyl-5-chlorobenzylidene)-(3-hydroxy-phenyl)acetohydrazide,

N-(2-hydroxy-5-fluorobenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2-hydroxy-6-methylbenzylidene)-(3,5-difluorophenyl)aceto-  
hydrazide,

N-(2-hydroxy-6-methylbenzylidene)-(3-fluorophenyl)acetohydra-  
zide,

N-(2-hydroxy-6-methylbenzylidene)phenyl acetohydrazide,  
N-[1-(4-hydroxyphenyl)ethylidene]-(3-hydroxyphenyl)aceto-  
hydrazide,

N-[1-(2,4-dihydroxyphenyl)ethylidene]-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2,4-dihydroxy-6-methylbenzylidene)-(3-methyl-5-methoxy-phenyl)acetohydrazide,

N-(2,4-dihydroxy-6-methylbenzylidene)-(3,5-dihydroxyphenyl)-  
acetohydrazide,

N-(2-hydroxy-4-carboxybenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2,3-dimethyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)-  
acetohydrazide,

N-(3,5-dimethyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2-acetoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-3-methoxybenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2-hydroxy-5-methoxybenzylidene)-(3-hydroxyphenyl)aceto-  
hydrazide,

N-(2-hydroxy-5-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-3-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

5

N-(2-hydroxy-3-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-6-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

10

N-(2-hydroxy-5-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(3-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-3-tert-butylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

15

N-(2-hydroxy-4-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-3-nitro-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

20

N-(2-hydroxy-4-methyl-5-chlorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2,6-dimethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

25

N-(2-hydroxy-3-fluorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-3-bromo-5-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

30

N-(2-hydroxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-4-methoxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

35

N-(2-hydroxy-4-acetoxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-4-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,



hydrazide,

N-(3-chloro-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

5

N-(2-hydroxy-3-bromo-5-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2,4,6-trimethylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

10

N-(3,5-dibromo-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2,4,5-trimethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

15

N-(2-methoxy-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(4-hydroxy-3-ethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

20

N-(2-methoxy-4-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(4-hydroxy-3-carboxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

25

N-(2-hydroxy-3-methoxy-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(4-carboxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2,4-dimethylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(4-trifluoromethylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,

30

zide,

N-(4-trifluoromethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

35

N-(2,4-dihydroxy-6-methylbenzylidene)-(3-hydroxy-5-methylphenyl)acetohydrazide,

N-(2,4-dihydroxy-6-methylbenzylidene)-(3-hydroxy-2-methylphenyl)acetohydrazide,

N-(2-hydroxy-4,6-dimethoxybenzylidene)-(3-hydroxyphenyl)-  
acetohydrazide,

5

and the pharmaceutically usable derivatives, salts, solvates and  
stereoisomers thereof, including mixtures thereof in all ratios.

10

6. Medicaments comprising at least one compound according to Claim  
1-5 and/or pharmaceutically usable derivatives, solvates and stereo-  
isomers thereof, including mixtures thereof in all ratios, and optionally  
excipients and/or adjuvants.

15

7. Use of compounds according to Claim 1-5 and the pharmaceutically  
usable derivatives, solvates and stereoisomers thereof, including  
mixtures thereof in all ratios, for the preparation of a medicament for  
the treatment and/or prophylaxis of diseases in which the inhibition,  
regulation and/or modulation of signal transduction by kinases plays  
a role.

20

8. Use according to Claim 7, where the kinase is SGK.

25

9. Use according to Claim 8 of compounds according to Claim 1-5 and  
the pharmaceutically usable derivatives, solvates and stereoisomers  
thereof, including mixtures thereof in all ratios, for the preparation of  
a medicament for the treatment of diseases which are influenced by  
inhibition of SGKs by the compounds according to Claim 1-4.

30

10. Use according to Claim 9 of compounds according to Claim 1-5 and  
pharmaceutically usable derivatives, solvates and stereoisomers  
thereof, including mixtures thereof in all ratios, for the preparation of  
a medicament for the treatment or prevention of diabetes, obesity,  
metabolic syndrome (dyslipidaemia), systemic and pulmonary  
hypertonia, cardiovascular diseases and renal diseases, generally in

35

any type of fibrosis and inflammatory process, cancer, tumour cells, tumour metastases, coagulopathies, neuronal excitability, glaucoma, cataract, bacterial infections and in antiinfection therapy, for increasing learning ability and attention.

5

11. Use according to Claim 10, where diabetes is diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy and microangiopathy.

10

12. Use according to Claim 10, where cardiovascular diseases are cardiac fibroses after myocardial infarction, cardiac hypertrophy, cardiac insufficiency and arteriosclerosis.

15

13. Use according to Claim 10, where renal diseases are glomerulosclerosis, nephrosclerosis, nephritis, nephropathy and electrolyte excretion disorder.

20

14. Use according to Claim 10, where fibroses and inflammatory processes are liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and arthrosis, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerodermatitis, cystic fibrosis, scarring and Alzheimer's disease.

25

15. Medicaments comprising at least one compound according to Claim 1-5 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

30

16. Set (kit) consisting of separate packs of  
(a) an effective amount of a compound according to Claim 1-5 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,

35

and

(b) an effective amount of a further medicament active ingredient.

5

10

15

20

25

30

35